CTLA4 and neoplasm: For patients with tumor PD-L1 = 0%, there is a moderate benefit of dual checkpoint blockade with anti-cytotoxic T-lymphocyte-associated protein 4 plus anti-PD-1 combined with chemotherapy over standard anti-PD-1 plus chemotherapy45.